Role of Endothelial Lipase in Plasma HDL levels in a Murine Model of Hypertriglycerideridemia

Hanayo Tanaka¹, Tatsuro Ishida¹, Thomas P. Johnston², Tomoyuki Yasuda¹, Tomomi Ueyama¹, Yoko Kojima¹, Ramendra K, Kundu³, Thomas Quertermous³, Yuichi Ishikawa⁴, and Ken-ichi Hirata¹

¹Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
²Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas, Kansas City Missouri, USA
³Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA
⁴Kobe University Graduate School of Health Sciences, Kobe, Japan

Aim: Hypertriglycerideridemia is the most common cause of low plasma high-density lipoprotein cholesterol (HDL-C) levels; however, the correlation between high triglyceride (TG) and low HDL-C remains unclear. Endothelial lipase (EL) is a determinant of plasma HDL levels. We investigated the role of EL in HDL metabolism in a murine model of acute hypertriglycerideridemia.

Methods and Results: To establish TG-dominant hyperlipidemia, $EL^{-/-}$ and wild-type (WT) mice were injected with Poloxamer-407 (P-407, 0.5 g/kg, i.p.). A single injection of P-407 resulted in a marked increase in plasma TG and cholesterol levels together with a decrease in HDL-C levels. Although plasma TG levels were similar in $EL^{-/-}$ and WT mice after P-407 injection, HDL-C levels were 80% higher and the HDL particle size was significantly larger in $EL^{-/-}$ mice than in WT mice. P-407 treatment inhibited plasma lipoprotein lipase activity and EL phospholipase activity, without decreasing their expressions. Adenovirus-mediated overexpression of EL in the liver reduced plasma HDL-C levels in both normo- and hyperlipidemic mice, while overexpression of catalytically inactive EL reduced HDL-C levels in hyperlipidemic mice. Cell culture experiments revealed that both catalytically active and inactive EL promoted cellular HDL uptake to the same extent.

Conclusion: EL regulates plasma HDL levels in mice in the normolipidemic as well as the acute hypertriglycerideridemic state. EL can modulate plasma HDL-CHOL levels through both its lipolytic and ligand-binding functions in hypertriglycerideridemic mice, while lipolytic activity appears to be the main determinant for its effects on HDL metabolism in normolipidemic mice.


Key words: Triglyceride, Cholesterol, High-density lipoproteins, Endothelial lipase

Introduction

There is growing recognition that metabolic syndrome is an alarmingly major worldwide public health problem, because it is arguably now the major cause of cardiovascular diseases and premature death. Characteristics of metabolic syndrome include abdominal obesity, atherogenic dyslipidemia, increased blood pressure, insulin resistance, and pro-thrombotic and pro-inflammatory states. As for dyslipidemia, elevated plasma triglyceride (TG) levels and low plasma concentrations of high-density lipoprotein (HDL)-cholesterol (CHOL) have emerged as diagnostic criteria. Patients with hypertriglycerideridemia frequently have low plasma levels of HDL-CHOL, and these lipid disorders synergistically contribute to an increased risk of coronary heart disease. Moreover, hypertriglycerideridemia, low HDL-CHOL, and qualitative changes in low-density lipoprotein (LDL) account for the typical dyslipidemia in insulin-resistant stages. There is thus great interest in determining the mechanisms respon-
sible for reduced HDL levels in hypertriglyceridemia associated with metabolic syndrome and insulin resistance.

Previous studies have indicated that hypertriglyceridermia per se can be a cause of low HDL levels. In addition, HDL-CHOL levels in hypertriglyceridemic patients are regulated by cholesteryl ester transfer protein (CETP), lecithin:cholesterol acyltransferase (LCAT), hepatic TG lipase (HL), and lipoprotein lipase (LPL); however, these plasma factors can account for only half of the variations in plasma concentrations of HDL-CHOL in hypertriglyceridemic patients, and indeed, it has been postulated that variations in HDL-CHOL levels in humans are approximately 50% genetically determined. Endothelial lipase (EL) is one of these genetic determinants of plasma HDL levels. Previous animal studies have documented an inverse correlation between EL expression and plasma HDL-CHOL levels. Association-based human genetic studies have shown that variations in the EL genomic locus are linked to differences in circulating HDL-CHOL levels. Plasma EL levels have been shown to be associated with plasma HDL levels in patients with metabolic syndrome. These lines of evidence imply that EL may play a role in the genesis of low HDL accompanied by hypertriglyceridemia or insulin resistance in metabolic syndrome.

Poloxamer 407 (P-407; Pluronic F-127®) is a block copolymer consisting of repeating polyoxylene and polyoxypropylene units and is categorized as a non-ionic surfactant polyol. It has been shown to produce a profound hypertriglyceridemia in rodents. A single injection of P-407 (0.25–1.0 g/kg, i.p.) in mice produced a 10-fold increase in plasma CHOL that peaked at 24 hours and had returned to control levels by 96 hours following treatment, while plasma TG levels changed even more markedly than CHOL levels following the administration of P-407. These effects are primarily believed to be the result of LPL and HL inhibition. Thus, P-407-induced TG-dominant hyperlipidemia resembles Type IV hypercholesterolemia in humans. In this study, we aimed to explore the effect of P-407 on EL expression and function, and to identify the role of EL in HDL metabolism in a P-407-induced murine model of acute hypertriglyceridemia.

Materials and Methods

Animal Preparation

All animal experiments were conducted at Kobe University Graduate School of Medicine according to the institutional Guidelines for Animal Experiments of the University Graduate School of Medicine according to the institutional Guidelines for Animal Experiments of the University Graduate School of Medicine

Analysis of Plasma Lipids

For lipid analysis, whole blood was collected by retro-orbital bleeding or cardiac puncture following an overnight fast. Plasma was collected by centrifugation at 8,000 g for 5 min at 4°C. Total CHOL, TG, and phospholipid (PL) levels were measured using commercially available kits (Wako Pure Chemicals, Tokyo, Japan). For separation of plasma lipoproteins by ultracentrifugation, 1.0 mL pooled plasma from 2–3 male mice was used, and CHOL, TG, and PL levels in each lipoprotein fraction were determined by biochemical assays.

Furthermore, plasma lipoprotein profiles and sizes were analyzed with an on-line dual enzymatic method for simultaneous quantification of CHOL and TG by HPLC (LipoSEARCH® from Skylight Biotech, Inc. (Akita, Japan) according to the specified procedure. Briefly, 200 µL of 20x saline-diluted sera was injected into two tandem connected TSK gel Lipropak XL columns (300 x 7.8 mm; Tosoh, Tokyo, Japan), and CHOL and TG contents in lipoproteins separated by size were determined using enzymatic reagents specially prepared by Kyowa Medex (Tokyo, Japan). Total CHOL and TG concentrations were calculated by comparing the total area under the chromatographic curves of a calibration standard of known concentration.

Adenovirus-Mediated EL Gene Transfer

Wild-type human EL, catalytically inactive human EL, in which the alanine (EL-S149A) was
substituted for the active site serine, or LacZ, were expressed by gene transfer. Recombinant adenoviruses encoding human EL (AdEL), human EL-S149A (AdEL-S149A), and LacZ (AdLacZ, a negative control) were constructed as described previously. Mice were intravenously injected via the tail vein with $1 \times 10^{11}$ particles of AdEL, AdEL-S149A, or AdLacZ. Forty-eight hours after the adenoviral injection, the mice were injected with P-407, and 16 hours later, blood was drawn for lipoprotein analysis.

**Determination of Cellular Uptake of HDL**

HDL (d = 1.063 to 1.215 g/mL) was isolated from healthy human plasma by sequential ultracentrifugation, dialyzed against PBS/EDTA, and labeled with the fluorescent probe 1′,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes). HDL was incubated for 8 hours at 37°C with 50 µL DiI in DMSO (3 mg/mL) for each milligram of protein. The labeled HDL was then re-isolated by ultracentrifugation and stored under N₂ gas.

Confluent monolayers of COS-7 cells were infected with a $1 \times 10^8$ multiplicity of infection (MOI) of AdLacZ, AdEL-WT, or AdEL-S149A for 24 hours, followed by incubation for 2 hours with 5 µL cholesterol/mL of DiI-labeled HDL in combination with a 50-fold excess of unlabeled HDL. Cells were washed twice with PBS containing 0.2% bovine serum albumin, and then twice with PBS only. Fluorescence intensity was measured on a FACScan (BD Biosciences, Franklin Lakes, NY), with excitation and emission wavelengths set at 520 nm and 580 nm. The results are expressed as the mean fluorescence intensity (MFI) and as a percentage of the MFI of AdLacZ-infected COS-7 cells. In some experiments, fluorescence intensity was measured with a laser-scanning confocal imaging system (BZ-8000; Keyence, Osaka, Japan). To confirm the level of transgene expression, 10 U/mL heparin was added to the culture medium, and EL expression in culture medium was evaluated by Western blotting.

**Lipase Expression Analysis**

Expressions of EL, HL, and LPL in mouse tissues or cultured cells were analyzed with RNase protection assays or real-time PCR, or with Western blotting utilizing an anti-human EL monoclonal antibody. For RNase protection assays, cDNA fragments of EL (coding from +1 to +281), LPL (coding from +164 to +395), and HL (coding from +237 to +410) cDNA were obtained with PCR using the following primers. Mouse EL; 5′-gatgcgaaacacggtttt-3′, and 5′-tcgctcatacatgaattg-3′. Mouse LPL; 5′-tagttccagcagcaagaaga-3′ and 5′-tagacacagagctctgtaatcgg-3′. Mouse HL; 5′-gaggccagagctggaaatc-3′ and 5′-gaagac-ggatctgctg-3′. PCR products were cloned into the pGEM T-easy vector (Promega, Madison, WI), and linearized with SpeI. Cyclophilin cDNA template was purchased from Ambion, Inc. (Austin, TX). [³²P]UTP-labeled antisense riboprobes were synthesized with T7 RNA polymerase, and the RNase protection assay was performed using an RPA III kit (Ambion). Protection of murine EL, LPL, HL, and cyclophilin transcripts resulted in a labeled fragment of 281, 232, 174 and 103 nucleotides, respectively. A Fujix BAS2000 bio-imaging analyzer (Fujifilm, Tokyo, Japan) was used to standardize the relative signal intensity of EL mRNA expression with that of cyclophilin mRNA. For real-time PCR, purified RNA from mouse tissue was reverse-transcribed using an ExScriptTM RT reagent kit (TaKaRa, Shiga, Japan).

Quantitative gene expression analysis was performed on an ABI PRISM 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA) using SYBR Green technology. PCR primers were purchased from TaKaRa as follows:

- Mouse LPL; 5′-gccgagacgagcaccatcgc-3′ and 5′-tgtccacactccggtaaatcga-3′.
- Mouse HL; 5′-gccatggcactagttgac-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Mouse EL; 5′-gtgctcagctgttggtggtg-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Mouse β-actin; 5′-cccttaaggccacggctgaa-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Human EL; 5′-attagggacccctgaggctttaagtg-3′, and 5′-atattctgcaacagcagcagcagcag-3′.
- Human GAPDH; 5′-agcatttcccctgaggctttaagtg-3′, and 5′-tagacacagagctctgtaatcgg-3′. The signal intensity of EL mRNA expression with that of cyclophilin mRNA. For real-time PCR, purified RNA from mouse tissue was reverse-transcribed using an ExScriptTM RT reagent kit (TaKaRa, Shiga, Japan).

Quantitative gene expression analysis was performed on an ABI PRISM 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA) using SYBR Green technology. PCR primers were purchased from TaKaRa as follows:

- Mouse LPL; 5′-gccgagacgagcaccatcgc-3′ and 5′-tgtccacactccggtaaatcga-3′.
- Mouse HL; 5′-gccatggcactagttgac-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Mouse EL; 5′-gtgctcagctgttggtggtg-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Mouse β-actin; 5′-cccttaaggccacggctgaa-3′, and 5′-gtgctcagctgttggtggtg-3′.
- Human EL; 5′-attagggacccctgaggctttaagtg-3′, and 5′-atattctgcaacagcagcagcagcag-3′.
- Human GAPDH; 5′-agcatttcccctgaggctttaagtg-3′, and 5′-tagacacagagctctgtaatcgg-3′.

**Lipase Assay**

Mouse blood was collected into EDTA-containing tubes before and 10 minutes after intravenous injection of heparin (150 U/kg). Plasma TG lipase activity was measured with the CONFLUORIP kit (Progen, Heidelberg, Germany). Phospholipase activity was quantified as described previously. In a subset of in vitro experiments, human umbilical vein endothelial cells, or COS7 cells which stably overexpress human EL, were incubated with P-407 for 24 hours. The culture medium was collected after the addition of heparin and concentrated 20–40 times for phospholipase assays.

**Statistical Analysis**

Data are expressed as the mean ± SE. Unpaired Studently t-test was used to identify significant differ-
ences between groups. One-way ANOVA was used to determine differences among three or four groups, with Bonferroni’s test used for post-hoc analysis. Repeated measures ANOVA was used to compare lipid fraction results obtained from HPLC. *P* values <0.05 were considered significant.

**Results**

**P-407 Induces Triglyceride-Dominant Hyperlipidemia**

Mouse plasma lipid profiles were determined with a biochemical assay. Under basal conditions, total CHOL in $EL^{-/-}$ mice approximately doubled compared to that WT mice (Fig. 1A). When P-407 was injected into these mice, the plasma showed marked hyperlipidemia, while the total CHOL level increased up to 12−15 mmol/L in both WT and $EL^{-/-}$ mice. The CHOL level after P-407 was moderately but significantly higher in $EL^{-/-}$ mice than in WT mice.

Plasma TG levels were low in these fasted mice at baseline (Fig. 1B), but P-407 administration resulted in a marked elevation of plasma TG levels in both mouse groups. That there was no difference in TG levels between mouse groups after P-407 injection (Fig. 1B) suggests that EL deficiency does not augment hypertriglyceridemia in this model.

**P-407 Increases VLDL, but Reduces the Level of HDL, which is Restored by EL Deficiency**

The lipoprotein analysis using ultracentrifugation provided direct evidence that the increase in CHOL in $EL^{-/-}$ mice at baseline reflects the 70% increase in the HDL fraction (Table 1). LDL-CHOL was slightly enhanced in $EL^{-/-}$, but VLDL-CHOL was not affected by EL deficiency. When mice were treated with P-407, VLDL-CHOL primarily increased, but the levels were similar for the two mouse groups. P-407 caused an increase in LDL-CHOL in both groups, with $EL^{-/-}$ mice showing a significantly higher LDL-CHOL level than WT mice. These increases in LDL-CHOL were considered a result of the catalytic action of EL on apoB-containing lipoproteins. In contrast, HDL-CHOL was reduced by 40% in response to P-407 in both groups. Interestingly, the HDL-CHOL level in $EL^{-/-}$ mice was still 80% higher than in WT after P-407 treatment, even though plasma TG levels were similar. These findings indicate that complete EL inactivation by gene deletion leads to an increase in the low level of HDL-CHOL in P-407-induced hypertriglyceridemia.

VLDL-TG levels were similar in $EL^{-/-}$ and WT mice. When mice were treated with P-407, VLDL-TG markedly increased, but there was still no significant difference in VLDL-TG between groups (Table 1). At baseline, HDL-TG was slightly higher in $EL^{-/-}$ than in WT mice, and was increased by P-407 without any difference in levels between groups. HDL-PL levels were higher in $EL^{-/-}$ than in WT mice both before and after P-407 injection, reflecting the absence of EL phospholipase activity. LDL-PL also increased in $EL^{-/-}$ mice before and after P-407 injection. VLDL-PL was not affected by EL deficiency.

**P-407 Increases HDL-TG and EL Inactivation Increases HDL-CHOL**

HPLC was used for further characterization of the lipoprotein profile (Fig. 2). When mice were treated with P-407, VLDL-CHOL markedly increased

---

**Fig. 1.** Plasma cholesterol and triglyceride levels after P-407 treatment.
P-407 was injected into wild-type (WT) and endothelial lipase-deficient ($EL^{-/-}$) mice, and plasma cholesterol (CHOL) and triglyceride (TG) levels were determined with biochemical assays. Data are expressed as the mean ± SE. *p* < 0.05 and †p < 0.01 vs. corresponding WT value (n=15 in each group).
Table 1. Fasting plasmas lipid and lipoprotein profile in WT and \( EL^{-/-} \) mice before and 16 hours after P-407 injection

<table>
<thead>
<tr>
<th></th>
<th>WT - P-47</th>
<th>( EL^{-/-} ) - P-47</th>
<th>( p ) value</th>
<th>WT + P-47</th>
<th>( EL^{-/-} ) + P-47</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol (mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-CHOL</td>
<td>1.74 ± 0.05</td>
<td>2.95 ± 0.08</td>
<td>&lt; 0.0001</td>
<td>0.99 ± 0.03</td>
<td>1.78 ± 0.16</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>LDL-CHOL</td>
<td>0.31 ± 0.03</td>
<td>0.58 ± 0.06</td>
<td>&lt; 0.05</td>
<td>0.95 ± 0.06</td>
<td>1.43 ± 0.08</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>VLDL-CHOL</td>
<td>0.18 ± 0.01</td>
<td>0.22 ± 0.03</td>
<td>NS</td>
<td>10.11 ± 0.18</td>
<td>11.14 ± 0.42</td>
<td>NS</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-TG</td>
<td>0.030 ± 0.005</td>
<td>0.044 ± 0.003</td>
<td>&lt; 0.05</td>
<td>0.266 ± 0.028</td>
<td>0.293 ± 0.024</td>
<td>NS</td>
</tr>
<tr>
<td>LDL-TG</td>
<td>0.095 ± 0.012</td>
<td>0.075 ± 0.003</td>
<td>NS</td>
<td>1.318 ± 0.057</td>
<td>1.302 ± 0.220</td>
<td>NS</td>
</tr>
<tr>
<td>VLDL-TG</td>
<td>0.305 ± 0.018</td>
<td>0.390 ± 0.048</td>
<td>NS</td>
<td>64.648 ± 1.841</td>
<td>63.886 ± 3.028</td>
<td>NS</td>
</tr>
<tr>
<td>Phospholipid (mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-PL</td>
<td>2.23 ± 0.10</td>
<td>3.55 ± 0.10</td>
<td>&lt; 0.0001</td>
<td>1.02 ± 0.04</td>
<td>2.17 ± 0.10</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>LDL-PL</td>
<td>0.20 ± 0.03</td>
<td>0.32 ± 0.04</td>
<td>&lt; 0.05</td>
<td>0.75 ± 0.09</td>
<td>1.30 ± 0.06</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>VLDL-PL</td>
<td>0.28 ± 0.06</td>
<td>0.36 ± 0.08</td>
<td>NS</td>
<td>11.38 ± 0.32</td>
<td>12.11 ± 0.44</td>
<td>NS</td>
</tr>
</tbody>
</table>

HDL, LDL, and VLDL fractions were obtained from 1.5 mL pooled plasma from 2–3 male mice by ultracentrifugation. Cholesterol (CHOL), triglyceride (TG), and phospholipid (PL) levels in each lipoprotein fraction were determined by biochemical assays. Values are expressed as the mean ± SE (mmol/L, \( n = 6-8 \) in each group).

in both mouse groups (Fig. 2B), thus causing a shift in lipoprotein fractions from HDL-CHOL (normolipidemic state) to predominantly VLDL/LDL (hyperlipidemic state). VLDL- and LDL-CHOL levels were similar in the two groups (Fig. 2B), while our ultracentrifugation study detected higher LDL-CHOL levels in \( EL^{-/-} \) mice (Table 1). HDL-CHOL was significantly reduced by P-407 in both groups, while \( EL^{-/-} \) mice still showed an 80% higher HDL-CHOL level than WT mice (Fig. 2B).

Most TG was found in the VLDL fraction at baseline (Fig. 2C), without any significant difference in VLDL-TG between WT and \( EL^{-/-} \) mice. When mice were treated with P-407, VLDL-TG markedly increased to 20–25 mmol/L in both groups, with similar levels for the groups (Fig. 2D). HDL-TG was increased after P-407 administration without any difference between WT and \( EL^{-/-} \) mice. These results indicated that P-407 increased the TG content and decreased the CHOL content in HDL fractions, while EL inactivation mainly enhanced the CHOL content of HDL particles. No chylomicrons were detected in these fasted mice, supporting the notion that the increase in plasma TG was not reflected in chylomicron-TG levels.

HDL particle size analysis using HPLC found that HDL particles were larger in \( EL^{-/-} \) mice than in WT under non-stimulated conditions (Fig. 2E), suggesting that EL promotes the remodeling of HDL particles. P-407 administration resulted in an increase in HDL particle size in both WT and \( EL^{-/-} \) mice. Interestingly, the HDL particle size in \( EL^{-/-} \) mice was still larger than that in WT mice after P-407 treatment.

**Plasma TG-Lipase Activity is Inhibited by P-407**

We measured the activities of two major plasma TG-lipases, LPL and HL, in post-heparin plasma and found that they were similar in both WT and \( EL^{-/-} \) mice at baseline (Fig. 3A). P-407 treatment markedly reduced TG-lipase activity in both groups by approximately 95%, consistent with previous reports. Notably, there was no difference in TG-lipase activity between groups.

Measurement of plasma phospholipase activity demonstrated that plasma phospholipase activity in \( EL^{-/-} \) mice was 40% lower than in WT mice at baseline. Following P-407 administration, plasma phospholipase activity decreased in WT \((p<0.05)\) but not in \( EL^{-/-} \) mice, while there was no difference in phospholipase activity between mouse groups (Fig. 3B). These findings suggested that EL activity in vivo was inhibited by P-407 administration.

**P-407 does not Reduce Lipase Expression**

EL is predominantly expressed by vascular tissues, while HL is expressed in the liver, and LPL in the heart, muscles, and liver. We evaluated mRNA expression of the lipases in these different tissues. RNase protection assays disclosed that LPL, HL and EL levels in the liver were not affected by P-407 (Fig. 4A). Similarly, LPL expression in the heart was not changed by P-407 treatment (Fig. 4B). EL expression in the mouse aorta was evaluated by real-time
PCR because of the limited amount of RNA isolated, and was found to increase significantly in response to P-407 (Fig. 4C). Western blotting revealed that EL protein expression increased in the aorta but did not change in the liver (Fig. 4D). Despite the increase in EL expression in the aorta, EL protein levels in post-heparin plasma were not significantly altered by P-407 treatment (data not shown). These findings suggest that P-407 inhibits lipase activities without decreasing the mRNA levels of the lipases evaluated.

Next we examined to what extent EL expression was affected in vitro by P-407 treatment. Human umbilical vein endothelial cells were stimulated with P-407 and EL mRNA was quantified with real-time PCR. The EL mRNA level increased in response to P-407 in a time- and dose-dependent manner (Fig. 5A, B), indicating that P-407 increases EL expression during the acute time course. To further investigate the effect of P-407 on EL enzymatic activity, we collected the culture medium of EL-overexpressing COS7 cells, and evaluated the phospholipase activities therein. As shown in Fig. 5C, P-407 significantly inhibited EL protein expression increased in the aorta but did not change in the liver (Fig. 4D). Despite the increase in EL expression in the aorta, EL protein levels in post-heparin plasma were not significantly altered by P-407 treatment (data not shown). These findings suggest that P-407 inhibits lipase activities without decreasing the mRNA levels of the lipases evaluated.
phospholipase activity in vitro, indicating that P-407 eliminates the action of EL, but not by decreasing its expression.

**Reduction of HDL is Mediated by the Lipolytic and Bridging Function of EL.**

It has been demonstrated that, besides lipolytic function, EL has a non-enzymatic bridging function between lipoproteins and the vascular wall. To determine the relative effects of the EL lipolytic function on HDL compared with the ligand-binding function, we injected the mice with AdEL (wild-type EL), AdEL-S149A (catalytically inactive mutant), and AdLacZ (control) from the tail vein. This procedure resulted in overexpression of the transgene only in the liver, while EL and EL-S149A protein were released into the plasma by treatment with heparin (Fig. 6A). AdEL injection resulted in a marked reduction in plasma HDL levels the next day, and this effect lasted for at least 28 days (Fig. 6B), as was also reported in previous papers. The injection of AdEL-S149A (Fig. 6B) or AdLacZ (data not shown) did not significantly affect plasma HDL levels under normolipidemic conditions in either mouse group.

Next, P-407-induced hyperlipidemia was generated in gene-transferred mice. When wild-type EL was overexpressed, plasma HDL levels were markedly reduced in both WT and EL−/− mice (Fig. 6C). Interestingly, when EL-S149A was overexpressed, plasma HDL levels were significantly reduced in hypertriglyceridemic mice (Fig. 6C), but the treatment had no significant effect on normolipidemic mice (Fig. 6B). This result suggests that the low HDL levels in WT mice after P-407 treatment may be mediated through the lipolytic activity of EL as well as its ligand-binding function. AdEL injection resulted in a significant reduction of plasma TG levels in P-407-treated WT and EL−/− mice, but AdEL-S149A injection did not (Fig. 6C).

To verify the molecular basis of the bridging function of EL in HDL metabolism, we finally examined the effects of AdEL-WT and AdEL-S149A on cellular uptake of DiI-labeled HDL. Confocal microscopy (Fig. 6D, top) or flow cytometry (Fig. 6D, bot-

**Fig. 4.** Expression of lipase members in P-407-treated mouse tissues.

A and B. Total RNA samples were extracted from the liver (A) and heart (B) of wild-type (WT) and endothelial lipase-deficient (EL−/−) mice, and expressions of EL, lipoprotein lipase (LPL), and hepatic lipase (HL) were analyzed by RNase protection assays. Cy, cyclophilin. C. Expression of EL in mouse aorta was analyzed with real-time PCR, and standardized by β-actin mRNA level. *p < 0.05 vs. vehicle (n=4). D. Tissue lysate of the liver or aorta was subjected to Western blotting for EL expression. Representative images are shown in A, B, and D (n=3–4).
tom) revealed that overexpression of EL-WT and EL-S149A resulted in enhanced uptake of HDL without significant differences in uptake between proteins. These findings support the notion that EL modulates plasma HDL levels through both its enzymatic and ligand-binding functions.

Discussion

Hypertriglyceridemia is the most common cause of low plasma HDL levels, and the mechanisms responsible for low HDL in hypertriglyceridemia have been previously studied. First, it was found that elevated plasma TG per se can lower HDL levels2, 4. An increase in plasma TG appears to promote the transfer of CHOL esters from HDL particles into TG-rich lipoproteins. This transfer is also promoted by CETP, which is the second cause of changes in HDL levels22; however, mice are known to lack CETP activity in plasma. For our study, we confirmed that CETP activity was not detectable in WT and EL−/− mice before and after P-407 injection (data not shown). The third factor that correlates with HDL-CHOL levels is LCAT activity, which is necessary for the generation of CHOL esters for HDL particles. Although it has been reported that LCAT activity is impaired in EL−/− mice23, we found no difference in the endogenous CHOL esterification rate between WT and EL−/− mice after P-407 treatment (data not shown). The fourth mechanism for low HDL levels in hypertriglyceridemia is the activity of TG-lipases, such as LPL or HL24, 25. When LPL-mediated lipolysis of TG-rich lipoproteins is blocked, HDL formation is disrupted26, making it likely that P-407 resulted in severe hypertriglyceridemia and defective HDL biosynthesis in our study. In P-407-induced hyperlipidemia, however, the activities of these lipases are almost completely inhibited to a similar extent in both mouse groups. Taken together, these findings suggest that the higher HDL level in EL−/− mice cannot be explained by changes in these known plasma factors. Regardless of whether mice were treated with P-407, EL−/− mice showed markedly higher HDL-CHOL levels than WT mice. EL may thus be a determinant of plasma HDL levels not only in the normolipidemic but also in the hypertriglyceridemic state induced by the administration of P-407.

It is believed that the effect of P-407 injection on plasma lipoprotein metabolism is primarily caused by the inhibition of plasma LPL and HL activity27, 28. In addition, P-407 was found to reduce the activity of cholesterol 7α-hydroxylase12, 29. As a result, and concomitant with defective HDL biosynthesis, catabolism of TG-rich lipoproteins was delayed and plasma TG was increased markedly. Moreover, P-407 treatment increased the size and TG content of HDL particles, and TG-rich HDL particles are unstable because of the dissociation of apo A-I and are rapidly degraded by EL and HL30. These qualitative changes in HDL composition induced by P-407 may accelerate HDL...
catabolism in the model used in our study. Maugeais, et al demonstrated that EL expression in mice resulted in a dose-dependent increase in plasma phospholipase activity, a fractional catabolic rate of HDL-apolipoprotein, and uptake of apoA-I in the kidney and liver. The increased HDL levels in P-407-treated EL−/− mice are therefore likely to be the result not only of increased HDL levels at the time of injection but also of a decrease in the catabolic rate of HDL in EL−/− mice.

In this study, we have shown that P-407 inhibits EL activity both in vivo and in vitro. Our results show that phospholipase activity is similar in P-407-treated WT mice and EL−/− mice, although there was a substantial level of residual phospholipase activity in the plasma. Because the phospholipase assay used in this study is not specific to EL phospholipase activity, it was speculated that residual phospholipase activity in these mice may reflect the activities of other phospholipases in plasma (Fig. 3B). If P-407 inhibits EL activity, however, both WT mice treated with P-407 and EL−/− mice are not supposed to possess active EL, so the difference in HDL-CHOL levels between P-407-administered WT mice and EL−/− mice cannot be

Fig. 6. Effects of EL overexpression on plasma lipids in P-407-treated mice. WT and EL−/− mice were injected with recombinant adenovirus encoding wild-type human EL (EL-WT), catalytically inactive human EL (EL-S149A) or LacZ (control). A, Western blotting for human EL expression in wild-type (WT) mice. B, Effect of EL overexpression on plasma HDL levels in normolipidemic states (without P-407). HDL-CHOL in EL−/− and WT mice markedly decreased by AdEL injection, while AdEL-S149A injection did not affect HDL-CHOL levels in these mice. C, Effects of EL gene transfer on plasma HDL-CHOL and TG in P-407-induced hypertriglyceridemic states. Overexpression of EL-WT resulted in a marked reduction of plasma HDL-CHOL levels both in WT and EL−/− mice, while EL-S149A moderately reduced HDL-CHOL levels (top). Overexpression of EL-WT modestly reduced plasma TG levels both in WT and EL−/− mice, while EL-S149A did not (bottom panel). D, COS7 cells were infected with AdLacZ, AdEL-WT, or AdEL-S149A, and cellular uptake of Dil-labeled HDL was evaluated by confocal microscopy (top) or flow cytometry (bottom). The culture medium was subjected to Western blotting for standardization of protein expression (middle). *p<0.05 and †p<0.01 vs. corresponding AdLacZ infection (n=6–8 in each group).
explained only by the phospholipase activity of EL. Since EL−/− mice have undergone genetic manipulation of the LIPG gene, they do not express EL. In contrast, P-407-treated WT mice do express EL, but it is catalytically inactive. In this context, EL has been shown to act as a molecular bridge between EL-expressing cells and lipoproteins, and mediates the binding and uptake of HDL holoparticles and selective uptake of HDL-associated cholesterol esters independent of its enzymatic activity. We therefore speculate that the presence of EL protein in P-407-treated WT mice, even if catalytically inactive, may, through its bridging function, promote the clearance of HDL from the plasma, and partly contribute to the low HDL levels in WT mice. Our EL gene transfer data lent credence to this assumption. When wild-type EL was overexpressed in P-407-treated mice, HDL-CHOL levels diminished to <0.1 mmol/L, suggesting that P-407 treatment did not completely inhibit exogenously produced excess EL activity. Interestingly, EL-S149A overexpression resulted in a marked reduction of HDL-CHOL levels, not in normolipidemia but in hypertriglyceridemia, although the differences between these conditions leading to these different results remains a matter of conjecture. It has been reported that the expression of EL-S149A did not reduce the HDL-CHOL level in WT and apoA-I transgenic mice but resulted in a moderate reduction of HDL levels in HL-deficient mice. This suggests that the ligand-binding function of EL modulates HDL metabolism when HL is inactive. Similarly, EL has been shown to provide an alternative pathway for free fatty acid uptake in LPL-deficient tissue. Kratky, et al. demonstrated that EL is upregulated where LPL activity is absent, and that EL activity may contribute to the tissue uptake of free fatty acids, and thus affect the metabolism of plasma lipoproteins. In the light of previous findings, we speculate that EL may modulate plasma HDL levels through its lipolytic and ligand-binding functions in the hypertriglyceridemic state where the activity of TG-lipases is inhibited. Because our study focused on the role of EL in acute hypertriglyceridemia, further studies are required to establish the role of EL in HDL metabolism associated with chronic and more physiologic hypertriglyceridemia.

A number of previous studies have suggested that EL is a pro-inflammatory and pro-atherogenic molecule. Qiu, et al. indicated that suppression of EL expression attenuates proinflammatory cytokine secretion and influences the lipid composition in macrophages. Moreover, EL expression has been found to be associated with inflammation in patients with metabolic syndrome with insulin resistance. EL expression has been reported to increase in mouse models of insulin resistance. In fact, EL deficiency reduced atherosclerosis in apolipoprotein-E-deficient mice. On the other hand, several studies have reported that EL may also have anti-inflammatory and anti-atherosclerotic effects. Ahmed, et al. demonstrated that HDL hydrolyzed by EL can activate PPARα, resulting in attenuated leukocyte adhesion. In addition, it was found that EL can hydrolyze not only HDL but also apoB-containing lipoproteins and promote the catabolism of apoB-containing lipoproteins. Further studies are thus needed to clarify the overall effect of EL inactivation on atherosclerosis.

To summarize, EL was shown to play a role in HDL metabolism in mice in the normolipidemic as well as the acute hypertriglyceridemic state. EL can modulate plasma HDL-CHOL levels through both its lipolytic and ligand-binding functions in hypertriglyceridemic mice, yet the lipolytic activity of EL appears to be the main determinant of its effects on HDL metabolism in normolipidemic mice. Targeted inactivation of EL was found to result in the inhibition of hydrolysis and catabolism of HDL, and can increase plasma HDL levels when HDL biosynthesis is disrupted. Thus, EL may represent a novel target for HDL-raising pharmaceutical interventions for patients with low HDL levels.

Acknowledgements

This study was supported by Grants-In-Aid for Scientific Research, Global and 21st Century COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Sakakibara Memorial Research Grant from the Japan Research Promotion Society for Cardiovascular Diseases, Hyogo Foundation for Science and Technology, Meiji Yasuda Life Foundation of Health and Welfare, and Suzuken Memorial Foundation.

References

4) Nikkilä EA, Taskinen MR, Sane T: Plasma high-density


10) Ma K, Gilingroglu M, Otvos JD, Ballantyne CM, Marion AJ, Chan L: Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA, 2003; 100: 2748-2753


32) Fuki IV, Blanchard N, Jin W, Marchadier DH, Millar JS, Glick JM, Rader DJ: Endogenously produced endothelial lipase enhances binding and cellular processing of plasma...


